The UK’s National Health Service is significantly expanding its Transform trial to address a critical gap in prostate cancer screening equity. Black men face twice the risk of developing prostate cancer compared to white men, yet have historically been underrepresented in screening programs. The expanded trial now actively recruits black men aged 50-69, lowering the entry age by a decade compared to other populations. This represents a strategic shift toward precision medicine and health equity in oncology. The Transform trial combines traditional PSA blood tests with MRI imaging to improve diagnostic accuracy and reduce both false negatives and false positives. Led by Professor Noel Clarke of The Christie NHS Foundation Trust, the initiative targets 300,000 participants and aims to establish evidence-based screening protocols that account for elevated genetic and biological risk in black populations. Read the full article on GMJ Newsroom.
Was this article helpful?
